Latest News and Press Releases

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent the...

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinicsThe program, launching this month, will run for a minimum of three years PARSIPPANY,...

Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which JKI will...

AJOVY® (Fremanezumab) reduzierte die monatlichen Migränetage (MMD) und monatlichen Kopfschmerztage (MHD) im Vergleich zu Placebo über einen Zeitraum von 12 Wochen bei pädiatrischen Patienten im Alter...

AJOVY® (frémanézumab) a permis de réduire de manière significative le nombre de jours de migraine mensuels (MMD, de l’anglais « monthly migraine days ») et le nombre de jours de céphalées mensuels...

AJOVY® (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1Efficacy consistent...

TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes, Teva’s...

TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the...

For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared...

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental...